Chrysalis Clinical Research

The trials here

What the 20 trials at this site are about, from their registry records.

Conditions

• Type 2 diabetes14 trials
• Obesity9 trials
• Chronic kidney disease2 trials
• Type 1 diabetes1 trial

Phase

• Phase 312 trials
• Phase 27 trials
• Phase 41 trial

Status

• Completed16 trials
• Active, not recruiting2 trials
• Recruiting2 trials

Lead sponsor

• Novo Nordisk A/S10 trials
• Eli Lilly and Company4 trials
• Hoffmann-La Roche2 trials
• Boehringer Ingelheim1 trial
• Carmot Therapeutics, Inc.1 trial
• and 2 more

Running trials

• Recruiting

  Research Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to Cagrisema

  NCT07817251· Phase 3· Novo Nordisk A/S· Source

  Contact: Novo Nordisk

• Recruiting

  A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 Diabetes

  NCT07668388· Phase 2· Novo Nordisk A/S· Source

  Contact: Novo Nordisk

• Active, not recruiting

  A Study of LY3938577 in Participants With Type 2 Diabetes Previously Treated With Basal Insulin

  NCT07215312· Phase 2· Eli Lilly and Company· Source

• Active, not recruiting

  A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity

  NCT06662383· Phase 3· Eli Lilly and Company· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Type 2 diabetes2 recruiting

Closed trials

• Recruiting

  A Study to Compare Different Doses of Tifeglipron (RO7795081) With Placebo or Semaglutide in People With Type 2 Diabetes

  NCT07112872· Phase 2· Hoffmann-La Roche· Source

• Completed

  A Study Evaluating the Effect of Daily Oral Tifeglipron (RO7795081) in Participants With Obesity or Overweight With at Least One Weight-Related Comorbidity

  NCT07081958· Phase 2· Hoffmann-La Roche· Source

• Completed

  GV101 in Healthy Obese Participants

  NCT06979505· Phase 2· Graviton Bioscience Corporation· Source

• Completed

  A Study to Learn About the Study Medicine Called PF-07976016 in Adults With Obesity

  NCT06717425· Phase 2· Pfizer· Source

• Completed

  A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both

  NCT06534411· Phase 3· Novo Nordisk A/S· Source

• Completed

  A Study of Enicepatide (CT-388) in Participants With Obesity or Overweight With at Least One Weight-Related Comorbidity

  NCT06525935· Phase 2· Carmot Therapeutics, Inc.· Source

• Completed

  A Research Study to See How Switching From a Daily Basal Insulin to a New Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine in Adults With Type 2 Diabetes

  NCT06340854· Phase 3· Novo Nordisk A/S· Source

• Completed

  A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)

  NCT06077864· Phase 3· Boehringer Ingelheim· Source

• Completed

  A Study Using Flash Glucose Measurements for a New Once-weekly Insulin (Insulin Icodec) in People With Type 2 Diabetes Who Have Not Used Insulin Before (ONWARDS 9)

  NCT05823948· Phase 3· Novo Nordisk A/S· Source

• Completed

  A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk

  NCT05803421· Phase 3· Eli Lilly and Company· Source

• Completed

  A Research Study to See How Well CagriSema Helps People With Type 2 Diabetes and Excess Body Weight Lose Weight

  NCT05394519· Phase 3· Novo Nordisk A/S· Source

• Completed

  A Research Study to Look Into How Semaglutide, Together With a Lower Dose of Insulin Glargine, Compares to a Higher Dose of Insulin Glargine Alone in People With Type 2 Diabetes (SUSTAIN OPTIMIZE)

  NCT05514535· Phase 3· Novo Nordisk A/S· Source

• Completed

  A Study of Insulin Efsitora Alfa (LY3209590) as a Weekly Basal Insulin Compared to Insulin Glargine in Adult Participants With Type 2 Diabetes on Multiple Daily Injections

  NCT05462756· Phase 3· Eli Lilly and Company· Source

• Completed

  A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Semaglutide (COMBINE 2)

  NCT05259033· Phase 3· Novo Nordisk A/S· Source

• Completed

  A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Insulin Glargine Taken Daily With Insulin Aspart (COMBINE 3)

  NCT05013229· Phase 3· Novo Nordisk A/S· Source

• Completed

  A Research Study Comparing RYBELSUS® to Other Blood Sugar Lowering Tablets in People Living in America With Type 2 Diabetes (REALYSE)

  NCT05035082· Phase 4· Novo Nordisk A/S· Source